医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ChemOn Selects Instem to Help Automate Preclinical Processes and Meet Growing Demand for SEND

2017年07月11日 PM10:00
このエントリーをはてなブックマークに追加


 

CONSHOHOCKEN, Pa.

Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that Chemon Inc. (Chemon) has purchased a comprehensive package of preclinical data collection, analysis and regulatory submissions management solutions to automate and optimize study related processes at its Non-Clinical Research Laboratory in Yongin, South Korea.

Founded in 2000, Chemon is a privately owned, non-clinical Contract Research Organization (CRO), headquartered in Suwon, offering a wide range of testing services including toxicity and efficacy, pharmacokinetics and in vitro pharmacology.

Following a detailed competitive evaluation, Chemon selected the Provantis® preclinical data management solution to automate preclinical study processes and deliver increased efficiencies in the collection, storage and reporting of preclinical data. Chemon will also be deploying Instem’s submit™ software suite for the creation and management of SEND (Standard for Exchange of Nonclinical Data) compliant datasets. Chemon will access Instem’s solutions via the SaaS delivery model, giving them cost-effective access to software functionality, maintenance and support.

Key Facts

Dr. Si-Whan Song, CEO, Chemon said “Instem is widely recognized as the leading organization in the field of preclinical IT solutions and we look forward to quickly realizing the benefits of our Provantis and submit-for-SEND deployments. These investments will enable us to take our service to the next level, delivering faster response times and improved data quality to our sponsors. Our submit purchase will further strengthen our competitive position, enabling us to provide consistent, accurate, high quality SEND datasets to our clients.”

Neil Donaldson, VP Sales Europe & Asia, Instem, commented “We are delighted and honored to welcome Chemon to our client community. As a leading voice for the creation of a more connected ecosystem in the life sciences industry, it is pleasing for us to see organizations such as Chemon turning to Instem to deploy cohesive, state-of-the-art technology solutions that remove process barriers and help create heightened efficiencies for them and their clients.”

About Chemon Inc.

Chemon Inc. is a privately owned, non-clinical Contract Research Organization (CRO), which was founded in 2000. Chemon Inc. is headquartered in Suwon, South Korea and also has a state of the art, GLP and AAALAC certified research laboratory in Yongin.

Chemon Inc. offers a wide range of testing services including toxicity and efficacy, pharmacokinetics and in vitro pharmacology.

For further information please visit http://chemon.co.kr/eng/index.php

About Instem

Instem is a global provider of leading software solutions and services that are helping over 500 clients bring their life enhancing products to market faster. We enable clients in the life sciences to more efficiently collect, analyze, report and submit high quality regulatory data, while maintaining compliance for their products around the world.

Instem’s portfolio of software solutions and consulting services increases client productivity by enhancing product development and management processes, while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making, leading to safer, more effective products.

Instem supports its global clients through offices in the United States, United Kingdom, France, Japan, China and India.

http://www.linkedin.com/company/instem/
https://www.facebook.com/Instem.software
https://twitter.com/Instemsoftware

View source version on businesswire.com: http://www.businesswire.com/news/home/20170711005772/en/

CONTACT

Press Contacts:
Instem
Gary Mitchell (US HQ)
610-941-0990
gary.mitchell@instem.com
or
Julie
Jones (UK HQ)
+44 (0) 1785 825600
julie.jones@instem.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • New CDISC Standard Empowers Smarter Research for Diabetic Kidney Disease
  • Dr. Reddy’s and CHD Bioscience Announce Global License and Commercialization Agreement for Phase III Clinical Trial Candidate for Mitigation of Surgical Site Infections
  • Dr. Reddy’s Q1 FY18 Financial Results
  • Cogstate Receives Positive FDA Notification Regarding Medical Device Regulatory Submission
  • ヤンセン、ダルナビルを基本とした初のHIV治療用シングルタブレットレジメンSYMTUZA™に対するCHMPの肯定的意見を取得